Analyst David Turkaly works at JMP and is focused on the Healthcare sector with 204 price targets and ratings documented since 2013 spanning on 14 stocks. Analyst's average stock valuation to be materialised ratio is 52.88% with an average time for price targets to be met of 270.46 days.
Most recent stock forecast was given on HAE, Haemonetics Corporation at 08-Nov-2022.
David Turkaly best performing recommendations are on STIM (NEURONETICS, INC).
The best stock recommendation documented was for AXGN (AXOGEN, INC) at 5/1/2018. The price target of $43 was fulfilled within 6 days with a profit of $4.65 (12.13%) receiving and performance score of 20.21.
Average potential price target upside